Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Watson

  • News

Executive Summary

Investment banking firm CIBC World Markets is retained to assist in the evaluation of possible alternatives, including possible divestiture, for its two sterile injectable manufacturing facilities in Phoenix, Ariz. and Cherry Hill, N.J. Watson acquired the facilities through its recent acquisition of Schein, completed Aug. 28 (1"The Pink Sheet" May 29, p. 27). Watson said it will continue to market the injectable products INFeD and Ferrlecit. Although INFeD is manufactured at the Phoenix facility, Watson will consider a contract manufacturing arrangement for the product. Watson also names former Schein Senior VP-Quality Donald Britt as Senior VP-corporate quality assurance

Table

View full table

Tags:
Latest Headlines

ICER Debuts Clinical Trial Diversity Assessment Framework

US FDA Wants Advice About Advisory Committees: Try Having Some?

Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives

Industry Calls For Caution Over EMA Supply Chain Recommendations

See All
UsernamePublicRestriction

Register

PS036617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By